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Abstract
Purpose To evaluate the effect of eculizumab on perceived fatigue in patients with anti-acetylcholine receptor antibody-
positive, refractory, generalized myasthenia gravis (MG) using the Quality of Life in Neurological Disorders (Neuro-QOL) 
Fatigue subscale, and to evaluate correlations between improvements in Neuro-QOL Fatigue and other clinical endpoints.
Methods Neuro-QOL Fatigue, MG Activities of Daily Living (MG-ADL), Quantitative MG (QMG), and the 15-item MG 
Quality of Life (MG-QOL15) scales were administered during the phase 3, randomized, placebo-controlled REGAIN study 
(eculizumab, n = 62; placebo, n = 63) and subsequent open-label extension (OLE). Data were analyzed using repeated-
measures models. Correlations between changes in Neuro-QOL Fatigue and in MG-ADL, QMG, and MG-QOL15 scores 
were determined at REGAIN week 26.
Results At REGAIN week 26, eculizumab-treated patients showed significantly greater improvements in Neuro-QOL Fatigue 
scores than placebo-treated patients (consistent with improvements in MG-ADL, QMG, and MG-QOL15 scores previously 
reported in REGAIN). Improvements with eculizumab were sustained through OLE week 52. Correlations between Neuro-
QOL Fatigue and MG-QOL15, MG-ADL, and QMG scores were strong for eculizumab-treated patients at REGAIN week 
26, and strong, moderate, and weak, respectively, for placebo-treated patients.
Conclusions Compared with placebo, eculizumab was associated with improvements in perceived fatigue that strongly cor-
related with improvements in MG-specific outcome measures.
Trial ID Registration: NCT01997229, NCT02301624.
Keywords Eculizumab · Myasthenia gravis · Fatigue · Neuro-QOL Fatigue · Quality of life · Terminal complement 
inhibition · Complement
Introduction
Patients with anti-acetylcholine receptor antibody-positive 
(AChR+), refractory, generalized myasthenia gravis (gMG) 
experience muscle weakness, which is associated with 
complement-mediated damage at the neuromuscular junc-
tion [1, 2]. Patients with MG experience muscle fatigability 
(difficulty initiating or sustaining muscle activities) [1, 3]. 
A complete list of study group investigators is included in 
electronic supplementary material.
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Perceived fatigue (a feeling of tiredness, lack of energy, and 
difficulty concentrating; referred to as fatigue hereafter) is 
also an important clinical issue for these patients and may be 
distinct from muscle weakness and fatigability [3–7].
Validated MG-specific assessments used to measure 
disease severity and response to intervention include the 
patient-reported MG Activities of Daily Living (MG-ADL) 
and 15-item MG Quality of Life (MG-QOL15) scales, and 
the physician-completed Quantitative MG (QMG) assess-
ment of muscle strength [8–10]. None of these evaluate the 
impact of fatigue in gMG. The Quality of Life in Neuro-
logical Disorders (Neuro-QOL) assessment is designed to 
measure health-related quality of life across 13 subscales 
in patients with neurological conditions [11]. Neuro-QOL 
has been validated in a range of disorders, including multi-
ple sclerosis, Parkinson’s disease, and epilepsy, but not in 
MG [12–14]. The Neuro-QOL Fatigue subscale comprises a 
19-item, patient self-assessment of fatigue that encompasses 
‘sensations ranging from tiredness to an overwhelming, 
debilitating, and sustained sense of exhaustion that decrease 
one’s capacity for physical, functional, social, and mental 
activities’ [15]. A short form Neuro-QOL Fatigue subscale 
is also available; this was recently validated in patients with 
MG [7].
Eculizumab is a humanized monoclonal antibody that 
binds to complement protein C5, inhibiting the activation 
of the terminal complement component proteins that are 
believed to mediate damage at the neuromuscular junction in 
AChR+ gMG [2, 16]. In the phase 3 REGAIN study, eculi-
zumab demonstrated clinically meaningful improvements in 
patients with AChR+ refractory gMG, evaluated using MG-
ADL, QMG, and MG-QOL15 assessments (NCT01997229) 
[17].
The current analysis investigated the effect of eculizumab 
versus placebo on fatigue in patients with AChR+ refrac-
tory gMG, and assessed the relationship between fatigue 
and MG-specific measures. We used the Neuro-QOL Fatigue 
subscale to evaluate changes in patients’ self-reported assess-
ment of fatigue during REGAIN and its open-label extension 
study (NCT02301624; interim analysis, 31 December 2017) 
[18]. We also measured the correlation between outcomes 
measured using the Neuro-QOL Fatigue subscale and the 
MG-ADL, QMG, and MG-QOL15 scales in REGAIN.
Methods
Study design
REGAIN was a 26-week, phase 3, randomized, double-
blind, placebo-controlled study evaluating eculizumab 
efficacy and safety [17]. Briefly, patients were randomized 
1:1 to receive eculizumab (n = 62; induction: 900 mg for 
4 weeks; maintenance: 1200 mg at week 4 and then every 
2 weeks until week 26) or placebo (n = 63) [17]. The pri-
mary endpoint was the change in MG-ADL total score 
with eculizumab versus placebo.
The Neuro-QOL Fatigue subscale was used to assess 
fatigue, and the MG-ADL, QMG, and MG-QOL15 scales 
were used to measure MG-specific activities of daily liv-
ing, muscle strength, and quality of life, respectively. In 
REGAIN, all assessments were performed at baseline (day 
1), every 4 weeks to week 20, and at week 26. MG-ADL 
and QMG assessments were also conducted at weeks 1, 2, 
and 3. Details of scoring for MG-ADL, QMG, and MG-
QOL15 during REGAIN have been reported previously; 
briefly, for each measure, a reduction from baseline total 
score indicates improvement [17]. The response scale 
for Neuro-QOL Fatigue items was: 1 = never; 2 = rarely; 
3 = sometimes; 4 = often; and 5 = always. The range of 
potential total scores was 19–95. Higher Neuro-QOL 
Fatigue subscale total scores indicate greater fatigue; a 
reduction from baseline total score indicates improvement 
[15].
Patients who completed REGAIN could enroll into the 
extension study [18]. Following a 4-week blinded induc-
tion phase, all patients received open-label eculizumab 
(1200 mg) at week 4 and every 2 weeks thereafter. Assess-
ments occurred as in REGAIN to week 26, then at week 40, 
week 52, and every 6 months [18].
Statistical analysis
A repeated-measures model was used to test whether 
changes in Neuro-QOL Fatigue total scores from baseline 
to REGAIN week 26 for eculizumab and placebo were equal 
(Fig. 1). Model-estimated changes from REGAIN baseline 
data were reported up to open-label study week 52 (interim 
analysis, 31 December 2017) (Fig. 1). To evaluate the treat-
ment effect on Neuro-QOL Fatigue subscale individual 
items at REGAIN week 26, a repeated-measures propor-
tional odds model was implemented using the GEEORD 
SAS Macro (Table 2) [19]. Missing scores were not imputed 
in either model.
Pearson correlation coefficients (r) were calculated for 
the treatment arms using observed changes from baseline to 
REGAIN week 26 for Neuro-QOL Fatigue total scores ver-
sus observed changes for MG-ADL, QMG, and MG-QOL15 
total scores (Fig. 2). The strength of association for absolute 
values of r was classified as follows: very weak, 0–0.19; 
weak, 0.2–0.39; moderate, 0.40–0.59; strong, 0.6–0.79; and 
very strong, 0.8–1 [20]. Within each treatment arm, the null 
hypothesis was r = 0.4 (the lower limit for moderate cor-
relations). For all evaluations, statistical significance was 
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established using a two-sided p value of less than 0.05, with-
out any multiplicity adjustment.
Results
Baseline demographics and characteristics were similar 
between treatment groups, with the exception of a higher 
proportion of Asian patients in the placebo group (Table 1). 
All patients were assessed using the Neuro-QOL Fatigue 
subscale (Table 1); mean (standard deviation) baseline total 
score was 64.1 (14.1) for the eculizumab group and 61.8 
(15.9) for the placebo group.
Eculizumab was associated with greater improvements in 
fatigue than placebo. At REGAIN week 26, patients receiv-
ing eculizumab had a model-estimated mean change from 
baseline Neuro-QOL Fatigue total score of − 16.3 (95% 
confidence interval [CI]: − 20.8, − 11.8) versus − 7.7 (95% 
CI − 12.1, − 3.3) for placebo (model-estimated mean differ-
ence − 8.6 [95% CI − 14.8, − 2.3; p = 0.0081]) (Fig. 1). By 
week 4 of the open-label study, patients who had received 
eculizumab in both studies (eculizumab/eculizumab arm) 
had reductions from REGAIN baseline of − 17.8 (95% 
CI − 22.5, − 13.0) compared with − 17.4 (95% CI − 22.0, 
− 12.9) for patients who received placebo during REGAIN 
and eculizumab during the open-label study (placebo/eculi-
zumab arm) (Fig. 1). Improvements in Neuro-QOL Fatigue 
score, from REGAIN baseline, were maintained through 
open-label study week 52 (–17.5 [95% CI − 22.5, − 12.5] 
and − 15.7 [95% CI − 20.5, − 10.9] for the eculizumab/ecu-
lizumab and placebo/eculizumab arms, respectively).
At REGAIN week 26, the proportional odds ratios for all 
19 Neuro-QOL Fatigue items were greater than 1, indicating 
that a greater proportion of eculizumab-treated patients than 
–25
–20
–15
–10
–5
0
Placebo/eculizumabEculizumab/eculizumabPlaceboEculizumab
REGAIN Open-label extension
C
ha
ng
e 
fro
m
 R
E
G
A
IN
 b
as
el
in
e 
in
LS
 m
ea
n 
N
eu
ro
-Q
O
L 
Fa
tig
ue
 to
ta
l s
co
re
 (9
5%
 C
I)
Time (weeks)
Patients, nb
bamuziluce lebal-nepOdnilb-elbuoD
BL
Double-blind
induction
16 20 26 40 521284262016128
06obecalP 616061626161
BL
61 65bamuzilucE 5657555661
4
61 57 57 56 54 54616060Placebo/eculizumab
55 51 49 48 48 48535552Eculizumab/eculizumab
*p < 0.05; **p < 0.01
**
* **
**
Fig. 1  Change in Neuro-QOL Fatigue subscale total score from 
REGAIN baseline to week 52 of the open-label study using a 
repeated-measures model.a aA repeated-measures model using 
the restricted maximum likelihood for the changes from baseline 
was used to compare the two treatment groups at each assessment 
visit and over time. The model included the following terms: treat-
ment, visit, treatment by visit interaction, pooled Myasthenia Gravis 
Foundation of America (MGFA) randomization stratification vari-
able (based on their MGFA classification at screening, patients were 
assigned to one of two categories: IIa/IIIa/IVa [a, symptoms predomi-
nantly affecting limb or axial muscles, or both] or IIb/IIIb/IVb [b, 
symptoms predominantly affecting oropharyngeal or respiratory mus-
cles, or both]), and Neuro-QOL Fatigue total score at baseline. bNum-
ber of patients who completed the assessment at each time point. 
Some patients did not complete all items of the questionnaire at every 
timepoint. When this occurred, total scores could not be computed 
at that time point. Missing scores were not imputed. BL baseline, CI 
confidence interval, Neuro-QOL Fatigue Quality of Life in Neurolog-
ical Disorders Fatigue subscale, REGAIN Eculizumab for REfractory 
GenerAlIzed MyastheNia Gravis
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Fig. 2  Correlation between 
change from REGAIN baseline 
to week 26, in Neuro-QOL 
Fatigue subscale total score 
and a MG-ADL, b QMG, and 
c MG-QOL15 total scores by 
treatment group (eculizumab, 
n = 54; placebo, n = 58). 
Improvements in Neuro-QOL 
Fatigue total score corre-
lated with improvements in 
a MG-ADL, b QMG, and c 
MG-QOL15 total scores more 
strongly in patients treated with 
eculizumab than in those who 
received placebo. Within treat-
ment arms, the null hypothesis 
was r = 0.4 (the lower limit 
for moderate correlations). CI 
confidence interval, MG-ADL 
Myasthenia Gravis-Activities 
of Daily Living, MG-QOL15 
15-item Myasthenia Gravis 
Quality of Life, Neuro-QOL 
Fatigue Quality of Life in 
Neurological Disorders Fatigue 
subscale, QMG quantitative 
myasthenia gravis
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placebo-treated patients selected lower scoring responses 
(i.e., more selected ‘never’ or ‘rarely,’ and fewer selected 
‘often’ or ‘always’) (Table 2). This was statistically signifi-
cant for 15 of 19 items (range of common odds ratios with 
p < 0.05: 1.8–2.9; Table 2), indicating that eculizumab treat-
ment was associated with milder fatigue than placebo.
For the eculizumab group, there were significant correla-
tions (i.e., different from r = 0.4) for changes in total score 
from baseline to REGAIN week 26 between Neuro-QOL 
Fatigue and MG-QOL15 (r = 0.74), MG-ADL (r = 0.70), 
and QMG (r = 0.64) (Fig. 2). For the placebo-treated group, 
a strong correlation for change from baseline to REGAIN 
week 26 was observed between Neuro-QOL Fatigue and 
MG-QOL15 (r = 0.65); conversely, correlations between 
Neuro-QOL Fatigue and QMG and MG-ADL were not 
significantly different from r = 0.4 (r = 0.45 [moderate] and 
r = 0.35 [weak]) (Fig. 2).
Discussion
This was the first use of the extended Neuro-QOL Fatigue 
subscale in patients with AChR+ refractory gMG. In 
REGAIN, levels of fatigue at baseline were generally 
Table 1  Baseline demographics 
and characteristics of patients in 
REGAIN
SD standard deviation
a Some patients did not complete all items of the questionnaire. When this occurred, total scores could not 
be computed and the specific item score is missing for those patients
Eculizumab (n = 62) Placebo (n = 63)
Age at diagnosis, years, mean (SD) 38.0 (17.8) 38.1 (19.6)
Age at first study dose, years, mean (SD) 47.5 (15.7) 46.9 (18.0)
Sex, n (%)
 Male 21 (34%) 22 (35%)
 Female 41 (66%) 41 (65%)
Race, n (%)
 Asian 3 (5%) 16 (25%)
 Black or African American 0 3 (5%)
 White 53 (85%) 42 (67%)
 Other 6 (10%) 2 (3%)
 BMI, kg/m2, mean (SD) 31.4 (9.0) 30.5 (8.4)
 Myasthenia gravis duration, years, mean (SD) 9.9 (8.1) 9.2 (8.4)
 Neuro-QOL Fatigue total score, mean (SD);  mediana 64.1 (14.1); 64.0 61.8 (15.9); 64.0
Neuro-QOL Fatigue item score, mean (SD);  mediana
 I felt exhausted 3.6 (0.82); 4.0 3.5 (1.09); 4.0
 I felt that I had no energy 3.7 (1.04); 4.0 3.7 (0.98); 4.0
 I felt fatigued 3.8 (0.88); 4.0 3.7 (0.91); 4.0
 I was too tired to do my household chores 3.5 (1.01); 4.0 3.3 (1.03); 3.0
 I was too tired to leave the house 3.2 (1.01); 3.0 3.2 (0.99); 3.0
 I was frustrated by being too tired to do the things I wanted to do 3.7 (1.08); 4.0 3.4 (1.21); 3.0
 I felt tired 3.8 (0.80); 4.0 3.8 (0.97); 4.0
 I had to limit my social activity because I was tired 3.6 (1.00); 4.0 3.4 (1.13); 4.0
 I needed help doing my usual activities because of my fatigue 3.0 (1.24); 3.0 2.9 (1.22); 3.0
 I needed to sleep during the day 3.3 (1.29); 3.0 3.4 (1.23); 4.0
 I had trouble starting things because I was too tired 3.3 (0.89); 3.0 3.1 (1.13); 3.0
 I had trouble finishing things because I was too tired 3.5 (0.99); 4.0 3.2 (1.06); 3.0
 I was too tired to take a short walk 3.4 (1.19); 4.0 3.1 (1.29); 3.0
 I was too tired to eat 2.6 (1.07); 3.0 2.3 (1.09); 2.0
 I was so tired that I had to rest during the day 3.7 (1.06); 4.0 3.6 (1.07); 4.0
 I felt weak all over 3.3 (1.07); 3.0 3.3 (1.13); 3.0
 I needed help doing my usual activities because of weakness 2.9 (1.24); 3.0 2.9 (1.18); 3.0
 I had to limit my social activity because I was physically weak 3.3 (1.23); 3.0 3.3 (1.04); 3.0
 I had to force myself to get up and do things because I was 
physically too weak
3.0 (1.18); 3.0 2.9 (1.17); 3.0
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Table 2  Neuro-QOL Fatigue individual item responses and results from a repeated-measures proportional odds model at REGAIN week 26
Parameter Treatment Observed responses for Neuro-QOL Fatigue items at REGAIN 
week 26
Repeated-measures model estimate 
for REGAIN week 26
1 = Never, 
n (%)
2 = Rarely, 
n (%)
3 = Some-
times, n (%)
4 = Often, 
n (%)
5 = Always, 
n (%)
Proportional 
odds ratio 
(95% CI)b
p value 
for odds 
 ratiob,c
p value for 
propor-
tional odds 
 assumptiond
I felt exhausted ECU (na = 57) 9 (15.8) 14 (24.6) 19 (33.3) 13 (22.8) 2 (3.5) 2.4 (1.3, 4.4) 0.0038 0.1099
PLC (na = 60) 5 (8.3) 9 (15.0) 25 (41.7) 16 (26.7) 5 (8.3)
I felt that I had no 
energy
ECU (na = 57) 9 (15.8) 15 (26.3) 21 (36.8) 9 (15.8) 3 (5.3) 1.9 (1.1, 3.5) 0.0322 0.5692
PLC (na = 60) 5 (8.3) 10 (16.7) 23 (38.3) 15 (25.0) 7 (11.7)
I felt fatigued ECU (na = 57) 7 (12.3) 16 (28.1) 22 (38.6) 8 (14.0) 4 (7.0) 1.8 (1.0, 3.4) 0.0467 0.3357
PLC (na = 60) 2 (3.3) 14 (23.3) 24 (40.0) 15 (25.0) 5 (8.3)
I was too tired to 
do my household 
chores
ECU (na = 56) 16 (28.6) 15 (26.8) 13 (23.2) 7 (12.5) 5 (8.9) 1.9 (1.0, 3.4) 0.0437 0.6454
PLC (na = 60) 11 (18.3) 11 (18.3) 19 (31.7) 17 (28.3) 2 (3.3)
I was too tired to 
leave the house
ECU (na = 57) 22 (38.6) 12 (21.1) 12 (21.1) 8 (14.0) 3 (5.3) 2.5 (1.4, 4.7) 0.0033 0.2162
PLC (na = 60) 12 (20.0) 11 (18.3) 20 (33.3) 15 (25.0) 2 (3.3)
I was frustrated by 
being too tired 
to do the things I 
wanted to do
ECU (na = 57) 20 (35.1) 14 (24.6) 11 (19.3) 8 (14.0) 4 (7.0) 2.5 (1.4, 4.5) 0.0032 0.4059
PLC (na = 60) 14 (23.3) 7 (11.7) 16 (26.7) 18 (30.0) 5 (8.3)
I felt tired ECU (na = 57) 9 (15.8) 9 (15.8) 22 (38.6) 12 (21.1) 5 (8.8) 2.3 (1.2, 4.4) 0.0092 0.3737
PLC (na = 60) 0 (0.0) 9 (15.0) 26 (43.3) 17 (28.3) 8 (13.3)
I had to limit my 
social activity 
because I was 
tired
ECU (na = 57) 15 (26.3) 16 (28.1) 13 (22.8) 9 (15.8) 4 (7.0) 2.6 (1.4, 4.7) 0.0026 0.6225
PLC (na = 60) 8 (13.3) 11 (18.3) 18 (30.0) 17 (28.3) 6 (10.0)
I needed help doing 
my usual activities 
because of my 
fatigue
ECU (na = 57) 26 (45.6) 10 (17.5) 10 (17.5) 7 (12.3) 4 (7.0) 2.3 (1.2, 4.2) 0.0104 0.5279
PLC (na = 60) 14 (23.3) 11 (18.3) 20 (33.3) 12 (20.0) 3 (5.0)
I needed to sleep 
during the day
ECU (na = 57) 14 (24.6) 14 (24.6) 13 (22.8) 10 (17.5) 6 (10.5) 1.5 (0.8, 2.7) 0.2164 0.4892
PLC (na = 60) 12 (20.0) 7 (11.7) 16 (26.7) 15 (25.0) 10 (16.7)
I had trouble start-
ing things because 
I was too tired
ECU (na = 57) 16 (28.1) 18 (31.6) 13 (22.8) 6 (10.5) 4 (7.0) 2.2 (1.2, 4.1) 0.0096 0.1930
PLC (na = 60) 15 (25.0) 7 (11.7) 18 (30.0) 13 (21.7) 7 (11.7)
I had trouble finish-
ing things because 
I was too tired
ECU (na = 57) 20 (35.1) 13 (22.8) 13 (22.8) 8 (14.0) 3 (5.3) 2.5 (1.4, 4.5) 0.0027 0.8333
PLC (na = 60) 12 (20.0) 11 (18.3) 18 (30.0) 13 (21.7) 6 (10.0)
I was too tired to 
take a short walk
ECU (na = 57) 19 (33.3) 14 (24.6) 11 (19.3) 9 (15.8) 4 (7.0) 1.5 (0.8, 2.7) 0.1896 0.9608
PLC (na = 60) 17 (28.3) 10 (16.7) 15 (25.0) 14 (23.3) 4 (6.7)
I was too tired to eat ECU (na = 57) 30 (52.6) 12 (21.1) 10 (17.5) 1 (1.8) 4 (7.0) 1.2 (0.6, 2.3) 0.5365 0.9093
PLC (na = 60) 25 (41.7) 17 (28.3) 11 (18.3) 7 (11.7) 0 (0.0)
I was so tired that I 
had to rest during 
the day
ECU (na = 57) 10 (17.5) 11 (19.3) 13 (22.8) 17 (29.8) 6 (10.5) 1.2 (0.7, 2.3) 0.4697 0.4873
PLC (na = 60) 9 (15.0) 8 (13.3) 19 (31.7) 14 (23.3) 10 (16.7)
I felt weak all over ECU (na = 57) 23 (40.4) 9 (15.8) 13 (22.8) 7 (12.3) 5 (8.8) 2.5 (1.4, 4.7) 0.0032 0.4309
PLC (na = 60) 12 (20.0) 12 (20.0) 14 (23.3) 17 (28.3) 5 (8.3)
I needed help doing 
my usual activities 
because of weak-
ness
ECU (na = 57) 26 (45.6) 12 (21.1) 10 (17.5) 6 (10.5) 3 (5.3) 2.3 (1.2, 4.2) 0.0095 0.3340
PLC (na = 60) 14 (23.3) 13 (21.7) 17 (28.3) 14 (23.3) 2 (3.3)
I had to limit my 
social activity 
because I was 
physically weak
ECU (na = 57) 19 (33.3) 18 (31.6) 6 (10.5) 10 (17.5) 4 (7.0) 2.9 (1.6, 5.3) 0.0006 0.1119
PLC (na = 60) 10 (16.7) 8 (13.3) 20 (33.3) 15 (25.0) 7 (11.7)
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consistent with previously published reports for MG; how-
ever, in these previous studies, fatigue was assessed using a 
variety of measures, and patients were not explicitly refrac-
tory to treatment [6, 7, 21].
At REGAIN week 26, eculizumab-treated patients were 
approximately twice as likely to report improved scores for 
the 15 of 19 subscale items where significant differences 
were observed, compared with placebo (range for odds 
ratios: 1.8–2.9; Table 2).
Patients who received eculizumab for the first time during 
the open-label study had similar improvements in fatigue to 
those seen with eculizumab during REGAIN. These were 
sustained through to week 52 of the open-label study and 
were consistent with previously reported improvements in 
MG-validated measures of disease burden (QMG, MG-ADL, 
and MG-QOL15) [17, 22]. The consistently strong, positive 
correlations between changes in Neuro-QOL Fatigue and 
MG-QOL15, MG-ADL, and QMG observed in eculizumab-
treated patients suggest that the effect of eculizumab on 
fatigue is a valid clinical outcome in this patient population. 
The greater variability in observed correlations in placebo-
treated patients may reflect the degree of similarity between 
the items assessed by the Neuro-QOL Fatigue subscale and 
those assessed by the MG-QOL15 (most similar, strong cor-
relation), the MG-ADL (some similarities, moderate correla-
tion), and the QMG (least similar, weak correlation).
Our findings suggest that the Neuro-QOL Fatigue sub-
scale may be used to assess the clinical impact of per-
ceived fatigue and the effect of therapeutic interventions 
in patients with AChR+ refractory gMG. Use of this scale 
demonstrated that eculizumab provided sustained, clinically 
meaningful improvements in fatigue. Our results contrib-
ute to the consistency and totality of the data demonstrating 
that eculizumab lowers the clinical burden in patients with 
AChR+ refractory gMG.
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week 26
Repeated-measures model estimate 
for REGAIN week 26
1 = Never, 
n (%)
2 = Rarely, 
n (%)
3 = Some-
times, n (%)
4 = Often, 
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5 = Always, 
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Proportional 
odds ratio 
(95% CI)b
p value 
for odds 
 ratiob,c
p value for 
propor-
tional odds 
 assumptiond
I had to force myself 
to get up and do 
things because I 
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weak
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The p values associated with the proportional odds assumption indicated that this assumption was upheld for each item
CI confidence interval, ECU eculizumab, Neuro-QOL Quality of Life in Neurological Disorders, PLC placebo
a Number of patients who completed the assessment at week 26; missing scores were not imputed for patients who did not complete the assess-
ment (ECU, n = 5 [n = 6 for ‘I was too tired to do my household chores’]; PLC, n = 3)
b Proportional odds ratios and p values are based on a repeated-measures ordinal regression (implemented using the GEEORD SAS Macro). The 
model has the ordinal response (for each parameter) at each visit as the dependent variable with terms for treatment, visit, and treatment by visit 
interaction, assuming exchangeable correlation structure. A higher odds ratio indicates that eculizumab-treated patients are more likely to answer 
in the lower response categories than those receiving placebo at week 26 for that item
c p values are not adjusted for multiple comparisons
d A p value for proportional odds assumption < 0.05 may indicate non-proportionality
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